Division of Johnson & Johnson
Latest From Janssen-Cilag GmbH
A plethora of new drugs moved closer to the EU market this week after the European Medicines Agency recommended that they should be approved.
Bluebird bio’s gene therapy Zynteglo, Akcea’s antisense drug Waylivra and BioMarin’s enzyme substitution therapy Palynziq were among the novel innovative medicines that were approved in Europe in 2019.
Five new drugs have been recommended for EU approval at the latest meeting of European Medicines Agency’s drug evaluation committee.
Seven new products, including the world’s first ever Ebola vaccine, are on track to receive EU-wide approval. Meanwhile, two drugs have failed to make the grade.
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Johnson & Johnson
- Senior Management
- Contact Info
Phone: 02 137 9550
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.